GALT Galectin Therapeutics Inc

$GALT 1. Early 2026 Summit Therapeutics requested increase in shares. Then announced a partnership in Sept with AstraZeneca for $2 bil (12% stake). They were in Phase 3 2. Early 2024, Novavax requested an increase in shares. In May 2024, before the meeting, company announced a $1.2 bil licensing agreement w/ Sanofi (4.9% stake). They were in Phase 2 3. In 2022, Horizon Therapeutics announced a meeting requesting an increase in shares. In Dec 2022 company acquired by Amgen for $27.8 bil. FDA approved drugs and multiple in Phase 1/Phase 2 4. Brickell Biotech scheduled meeting to vote on RS and increase in shares from 300 to 525 million in May 2022 . Before the meeting, a definitive purchase agreement by Botanix Pharmaceuticals. They were in Phase 3 5. Late 2022 CinCor Pharma sought out either issuance of new shares or execution of a dilutive secondary offering to fund ongoing trials. In January 2023, the company was acquired by AstraZeneca for $1.8 bil. They were in Phase 2 Is there more?

$GALT Assuming on September 30th, the Company has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA). If everything is cleared, they may start Ph3 in November, 2026. Most of the time, the company has to hired more employees to prepare for ph3 study. But at this time, still have no openings and don’t have enough money to start ph3 by themselves? FDA green light 🚥 then announce partnership or BO? Pick your choice.

$GALT One has to take a step back and look at the overall landscape. The Journal of Hepatology has an article in press "EASL-EASD-ESMO guidance on the use of resmetirom and semaglutide in MASH targeted therapy." As stated in the abstract- "In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH- targeted treatment until further data establish liver- related benefits." My opinion- unrelated to liver related benefits, safety for cirrhosis use is very unclear with these agents, as well as the FGF21 agents that were bought out by BP. I see no other new therapeutic agents for cirrhosis in the 2026 AASLD abstracts. I believe we stand alone. Good luck to all.

$GALT They're not lookking to partner, they're looking for a buyout. I was following some bread crumbs and dug this up, amended lease renewel terms, option to close their offices early.

$GALT Joel gets LOADS of credit here. This is what we call a well-run company. Not based on hype and fluff. Methodical and calculated. In the social media era many people fall for who can shout louder. We are fortunate to have a CEO who does not pay attention to the hysteria and does his job the right way. Thats why we are in this position. Thank you JL for getting us here

$GALT That phase 3 should be a confirmational outcomes trial with AA approved when the trial begins. Similar to what Madrigal did but using a hard clinical endpoint to fulfill subpart H and not a BS surrogate biopsy.

$GALT I loaded up new funds into my account but can’t even buy common shares until these extra funds settle in a few days. Basically they’re saying this stock has risk usually associated with options trading 🙄 again in effort to minimize retail purchasing I’m sure. Regardless, I’m holding full size and will load the extra in a few days.

$GALT Congratulations Joel and the entire management team! You all have been doing extremely well, have helped investors to go through this excellent stage, and I am sure that you all will be able to save many lives from this miracle drug in the near future! Very nice to chat with you Joel over the phone a while back! GLTA!

$GALT FIGHT BACK AGAINST THESE PEOPLE SPREADING FALSE INFORMATION. In ts Q1 filing GALT said it currently did not have plans or funding to undertake another clinical trial and reiterated dependence on strategic partnerships and outside capital. The additional room for shares in today's filing is obviously for a strategic partner to buy-in. GALT is not going on a hiring spree to run p3 on their own, it will use the manpower of the big pharma partner. Connect the dots.

$GALT short term trend lines meet this Thursday, if we get disappointed yet again down to mid $2's may be in play. In the event of a pullback would like to see 200DMA ($3.30) hold. Expecting just a Phase 3 submittal PR. Hoping for partnership/BO, which hopefully comes at the same time...but may come in the days or weeks following Phase 3 PR. If we don't get anything at all, low $1's wouldn't surprise me. Retail is tired of getting the run around, investor sentiment is down, and the market being in the gutter does us no favors.

$GALT Hoping that the good guy's win- for the patients, the shareholders, and to stick it to the shorts who have attempted to destroy this company. Good luck everyone.

$GALT Step 1 = BTD. Breakthrough Therapy Designation gets Galectin more frequent/intensive FDA touchpoints and buys them the ability to negotiate what counts as an adequate AA endpoint before they file, rather than finding out at review. This is the same move Merck, BMS, etc. make before filing an oncology AA on a response-rate or PFS surrogate BTD doesn't approve anything, it changes who's in the room when the endpoint gets negotiated. Step 2 = the endpoint pitch. With that negotiating position, the filing becomes: "prevention of incident esophageal varices in compensated MASH cirrhosis without baseline varices" is the Subpart H endpoint. It was reached at p=0.04 in the pre-specified per-protocol population the one clean statistically significant result out of NAVIGATE, playing the same role a positive secondary/subgroup result plays in an oncology surrogate package.

$GALT No new positions. No funds for a phase 3. Ongoing active discussions with financial and strategic partners. Early lease termination clause. Increased legal costs in the last quarter. 100 million of debt converted to equity. A ceo unqualified to run a company holding an international phase 3. An octogenarian majority owner and cob. Why would they risk running their own phase 3 for such a valuable drug and for an investment in which they’ve committed hundreds of millions and years of work? And succeeded against the odds of Covid. This is the time for bp resources, reputation, expertise and funds The drug is too important for them to do it on their own. Pretty sure they’ve always had a partner standing by but phase 3 protocol was required for the partners board to sign the deal.

$GALT This is the largest increase trend in years. Today’s TipRanks sampling of 880K investor portfolios showing how many new people are adding GALT to their portfolio. Should soon push through the support level to move the price up.

$GALT Step 3 = the consistency argument. 3524 and 0253 are doing exactly what a sponsor's internal "robustness" slide does in an oncology briefing book: showing the effect holds up across independently-defined risk strata (Baveno, ELF, ANTICIPATE-NASH), so it doesn't read as a single lucky cut of the data. Step 4 = the externally-sourced causal chain. 2529 and 1514 are the non-sponsor literature a company leans on to argue the surrogate is "reasonably likely to predict clinical benefit" independent epidemiology showing the endpoint sits on a real causal path to decompensation and mortality, rather than Galectin having to assert that linkage itself. That's the structure big pharma uses and it's a recognizable playbook. Will the FDA agree? I think so I think we win and shorts get destroyed in a manner they never imagined.

$GALT Blocking a couple of posters now whose posts are, for the most part, worthless to me. It's one way to elevate my reading experience on this board.

$GALT RIchard U might be working on a much larger announcement to go with the FDA submission

$GALT Charles Schwab.... last year they restricted investors from buying online.. had to place a phone call ... do you recall?

$GALT The funny thing about shorts? They all think they’ll be the first to cover. Unfortunately the exit door doesn’t get wider when everyone starts running. 😂 so my advice cover while you can.

$GALT That article from Harvard, in " Metabolism " Sept 2026, with the accompanying editorial, cited our Hepatology Belapectin paper. "Metabolism" is an a very high impact journal, ranked in the top 4 percent of all endocrinology, metabolism and diabetes journals).